CNS Pharmaceuticals Inc Market Cap ($7.31 Million)
Market Cap & Net Worth: CNS Pharmaceuticals Inc (CNSP)
CNS Pharmaceuticals Inc market cap. CNS Pharmaceuticals Inc (NASDAQ:CNSP) has a market capitalization of $7.31 Million ($7.31 Million) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27710 globally and #5730 in its home market, demonstrating a 5.26% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CNS Pharmaceuticals Inc's stock price $5.00 by its total outstanding shares 1461449 (1.46 Million). Also see CNSP cash generation efficiency for how efficiently the company converts equity into cash flow.
CNS Pharmaceuticals Inc Market Cap History (2019–2026)
CNS Pharmaceuticals Inc market cap history from 2019 to 2026. Data shows change from $8.66 Billion to $7.31 Million (-64.47% CAGR). Check CNSP stock price and chart for real-time trading data and today's change.
Index Memberships
CNS Pharmaceuticals Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.00% | #787 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.00% | #2539 of 3165 |
Weight: CNS Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
CNS Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CNS Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore CNS Pharmaceuticals Inc (CNSP) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CNSP by Market Capitalization
Companies near CNS Pharmaceuticals Inc in the global market cap rankings as of November 1, 2026. Also see CNS Pharmaceuticals Inc asset portfolio for a full breakdown of the balance sheet.
Key companies related to CNS Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of CNS Pharmaceuticals Inc (2019–2026)
Market capitalization of CNS Pharmaceuticals Inc from 2019 to today. Between 2019 and today, CNS Pharmaceuticals Inc's market cap moved from $8.66 Billion to $ 7.31 Million, with a yearly change of -64.47%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $7.31 Million | -4.76% |
| 2025 | $7.67 Million | +4260.47% |
| 2024 | $175.96K | -99.81% |
| 2023 | $92.80 Million | -47.08% |
| 2022 | $175.37 Million | -88.60% |
| 2021 | $1.54 Billion | -60.56% |
| 2020 | $3.90 Billion | -54.94% |
| 2019 | $8.66 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of CNS Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.31 Million USD |
| MoneyControl | $7.31 Million USD |
| MarketWatch | $7.31 Million USD |
| marketcap.company | $7.31 Million USD |
| Reuters | $7.31 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CNS Pharmaceuticals Inc
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate ca… Read more